Entero Healthcare Solutions Limited
ENTERO.NS
National Stock Exchange of India1,172.40
INR
-37.70
- -
Entero Healthcare Solutions Limited
ENTERO.NS
(National Stock Exchange of India)
Recent
price
1,172.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Entero Healthcare Solutions Limited, founded in 2018 and headquartered in Mumbai, India, operates as a technology-driven integrated healthcare products distribution company serving retail pharmacies, hospitals, healthcare practitioners, and clinics across more than 500 districts nationwide. The company distributes a comprehensive portfolio of over 80,600 SKUs encompassing pharmaceuticals, surgical products, medical devices, over-the-counter medications, nutraceuticals, and vaccines from more than 2,700 pharmaceutical and healthcare manufacturers; it supplies over 95,300 retail pharmacies and healthcare practitioners as well as more than 3,500 hospitals including corporate chains through a network of 104 warehouses; technology platforms such as Entero Direct for order fulfillment and procurement, Entero CRM for customer relationship management, Entero ERP for enterprise resource planning, and Teqtic enhance demand generation, supply chain efficiency, and customer retention; consumer brands under Entero Surgicals including Carent for health and personal care items like thermometers, blood pressure monitors, and adult diapers, Entros for mobility aids such as wheelchairs and walkers, Safent for safety products, and Glovent for hand gloves complement its offerings. Recent inorganic growth includes the completion of five acquisitions between July and October 2025 adding approximately ₹545 crore in proforma FY25 revenues, with binding agreements for two additional MedTech-focused entities targeting over ₹1,000 crore in total acquisition revenue through seven deals; planned acquisitions encompass an 80% stake in Bioaide Technologies Private Limited valued at ₹311-360 million and a 51% stake in Anand Chemiceuticals Private Limited valued at ₹2.1-2.3 billion to bolster medical devices distribution and healthcare turnkey projects; earlier deals such as Ramson Medical Distributors, Anand Medical Distributors, Shree Enterprises, and Radha Swami Medico House announced in 2024-2025 further expand its geographic footprint and product capabilities. Entero maintains corporate offices in Mumbai and registered offices in Faridabad, Haryana, positioning it among India's top three healthcare distributors by revenue with robust Q2 FY26 performance reflecting 21% revenue growth and 34% net profit increase.